FDA-Regulated Study of Cord Blood Stem Cells to Treat Acquired Hearing Loss Launches

 

FDA-Regulated Study of Cord Blood Stem Cells

to Treat Acquired Hearing Loss Launches

Signals Potential of Newborn Stem Cells in Regenerative

Medicine for Common Disorders

CORD BLOOD REGISTRY LOGO

“Cord Blood Registry® (CBR®), the world’s largest and most experienced newborn stem cell company, announces the start of a U.S. Food and Drug (FDA)-regulated study being conducted at Florida Hospital for Children in Orlando to investigate the use of a child’s stem cells from their own stored umbilical cord blood as a treatment for acquired sensorineural hearing loss. ”